Can Hypothyroidism Cause Elevated ALT and AST? Thyroid-Liver Connection

• Hypothyroidism can directly cause elevated ALT and AST through multiple mechanisms including reduced hepatic blood flow, lipid metabolism disruption, and cholestasis
• Up to 55% of patients with untreated hypothyroidism may have abnormal liver function tests, with ALT being the most commonly elevated enzyme
• The thyroid-liver connection is bidirectional: thyroid disease affects the liver, and liver disease alters thyroid hormone metabolism
• Treating hypothyroidism with appropriate levothyroxine therapy typically normalizes liver enzymes within 3-6 months
• Patients with unexplained elevated liver enzymes should be screened for thyroid dysfunction, as it is a frequently overlooked cause

The thyroid and the liver have a deeply intertwined physiological relationship that many patients and even some clinicians underestimate. To understand the question, "can hypothyroidism cause elevated ALT and AST?", we must first appreciate how these two organs interact.

How Thyroid Hormones Affect the Liver

Thyroid hormones, primarily thyroxine (T4) and triiodothyronine (T3), are critical regulators of hepatic function. The liver expresses thyroid hormone receptors throughout its tissue, and thyroid hormones influence virtually every aspect of liver metabolism:

• Basal metabolic rate regulation: T3 increases the liver's oxygen consumption and energy expenditure, affecting how efficiently liver cells function
• Lipid metabolism: Thyroid hormones stimulate hepatic LDL receptor expression, promote cholesterol clearance, and regulate fatty acid synthesis and oxidation
• Bile acid synthesis and secretion: T3 stimulates cholesterol 7-alpha-hydroxylase (CYP7A1), the rate-limiting enzyme in bile acid synthesis, and promotes bile flow
• Carbohydrate metabolism: Thyroid hormones influence hepatic gluconeogenesis and glycogenolysis
• Protein synthesis: T3 regulates the production of numerous hepatic proteins, including coagulation factors and carrier proteins
• Hepatic blood flow: Thyroid hormones maintain cardiac output and splanchnic blood flow, ensuring adequate perfusion of the liver

When thyroid hormone levels are deficient, as in hypothyroidism, all of these processes are impaired, creating multiple pathways through which liver enzyme elevations can occur.

How the Liver Affects Thyroid Hormones

The relationship is bidirectional. The liver plays essential roles in thyroid hormone metabolism:

• Deiodination: The liver contains type 1 deiodinase (D1), which converts the relatively inactive T4 to the active T3, and also inactivates T4 to reverse T3 (rT3)
• Thyroid hormone transport: The liver produces thyroxine-binding globulin (TBG), transthyretin, and albumin, the proteins that transport thyroid hormones in the bloodstream
• Thyroid hormone conjugation and excretion: The liver conjugates thyroid hormones with glucuronic acid and sulfate for biliary excretion
• Enterohepatic circulation: Thyroid hormones excreted in bile are reabsorbed in the intestine, and this cycle depends on healthy liver and gut function

When liver disease is present, these processes are disrupted, leading to altered thyroid hormone levels that can complicate both diagnosis and treatment.

Hypothyroidism elevated ALT and AST through several well-characterized mechanisms. Understanding these pathways helps explain why the enzyme elevation occurs and why it resolves with appropriate thyroid hormone replacement.

Mechanism 1: Reduced Hepatic Blood Flow

Hypothyroidism reduces cardiac output by decreasing heart rate and stroke volume. Studies have demonstrated that moderate to severe hypothyroidism can reduce hepatic blood flow by 25-40%. This reduction in perfusion causes relative ischemia of hepatocytes, particularly in the centrilobular region (zone 3) of the liver lobule, which is the area most susceptible to reduced oxygen supply.

Ischemic hepatocytes develop membrane instability and leak intracellular enzymes, including ALT and AST, into the bloodstream. This mechanism typically produces mild to moderate enzyme elevation (1.5-3 times the upper limit of normal) and is rapidly reversible with thyroid hormone replacement.

Mechanism 2: Non-Alcoholic Fatty Liver Disease (NAFLD)

Perhaps the most clinically significant connection between hypothyroidism and liver enzyme elevation is the increased risk of NAFLD. Multiple large epidemiological studies have established hypothyroidism as an independent risk factor for NAFLD, even after controlling for body weight, diabetes, and other metabolic risk factors.

A meta-analysis published in the Journal of Clinical Endocrinology and Metabolism found that patients with hypothyroidism had a 1.4-fold increased odds of having NAFLD compared to euthyroid individuals. The mechanisms include:

In this scenario, hypothyroid liver function tests show a pattern identical to typical NAFLD: ALT is higher than AST, with the De Ritis ratio typically below 1.0. GGT may also be mildly elevated, and ultrasound reveals increased hepatic echogenicity consistent with steatosis.

Mechanism 3: Cholestasis

Hypothyroidism reduces bile flow (cholestasis) by decreasing bile acid synthesis and reducing the expression of bile salt export pumps on hepatocyte membranes. This cholestatic effect can cause mild elevation of alkaline phosphatase, GGT, and sometimes bilirubin, in addition to ALT and AST.

The cholestatic pattern of hypothyroidism is typically mild and not associated with the severe itching or jaundice seen in primary biliary cholangitis or other cholestatic liver diseases. However, in severe untreated hypothyroidism (myxedema), more significant cholestasis can occur.

Mechanism 4: Myopathy

Hypothyroidism can cause a metabolic myopathy (muscle disease) that affects skeletal muscles throughout the body. This myopathy causes the release of muscle-derived enzymes, including AST and creatine kinase (CK), into the bloodstream. Because ALT is also present in small amounts in skeletal muscle, hypothyroid myopathy can contribute to both AST and ALT elevation, though AST elevation is typically more pronounced from this mechanism.

Hypothyroid myopathy is characterized by:

• Elevated CK levels (often markedly elevated, sometimes >1000 U/L)
• Muscle aches, stiffness, and weakness
• AST elevation that is proportional to CK elevation
• ALT elevation that is relatively mild compared to AST

Mechanism 5: Hepatocyte Membrane Permeability Changes

Thyroid hormones directly regulate the structural integrity of cell membranes, including those of hepatocytes. In hypothyroidism, altered membrane lipid composition and reduced Na+/K+-ATPase activity increase hepatocyte membrane permeability, allowing enzymes to leak out even without overt cell death. This mechanism produces very mild enzyme elevation and is fully reversible with treatment.

Research has quantified the frequency and patterns of liver function test abnormalities in patients with overt and subclinical hypothyroidism.

Prevalence Data

These data demonstrate that even subclinical hypothyroidism, defined as elevated TSH with normal free T4 levels, is associated with a measurably increased prevalence of liver enzyme abnormalities.

Typical Enzyme Pattern in Hypothyroidism

The liver enzyme pattern most commonly seen in hypothyroidism is:

• ALT: Mildly elevated (1.5-3x upper limit of normal), usually the most prominently elevated transaminase
• AST: Mildly elevated (1-2x upper limit of normal), typically lower than ALT
• GGT: Mildly elevated in approximately one-third of patients
• Alkaline phosphatase: May be elevated due to both bone and liver isoenzymes; thyroid disease can affect bone turnover
• Bilirubin: Usually normal; mildly elevated in severe cases
• CK: Often elevated, particularly in hypothyroid myopathy, helping distinguish thyroid-related enzyme elevation from primary liver disease

When a patient presents with elevated liver enzymes and known or suspected hypothyroidism, the diagnostic approach should be systematic and address both the thyroid and hepatic components.

Step 1: Confirm Thyroid Status

Step 2: Characterize the Liver Enzyme Pattern

Order a comprehensive liver panel including ALT, AST, GGT, alkaline phosphatase, total and direct bilirubin, albumin, and INR. Additionally, check CK to assess for myopathy contribution.

The pattern of enzyme elevation helps guide the differential diagnosis:

Step 3: Evaluate for Co-Existing Conditions

Because hypothyroidism is associated with other autoimmune conditions and metabolic disorders, screening for co-existing liver diseases is important:

• Viral hepatitis (HBsAg, anti-HCV) - autoimmune thyroid disease can co-occur with viral hepatitis
• Autoimmune hepatitis (ANA, SMA, anti-LKM) - overlaps with Hashimoto thyroiditis in up to 5% of cases
• Primary biliary cholangitis (AMA) - associated with autoimmune thyroid disease
• Metabolic syndrome (fasting glucose, lipid panel) - hypothyroidism increases metabolic risk
• Hemochromatosis (iron studies, ferritin) - iron overload can affect both liver and thyroid

Step 4: Imaging

Abdominal ultrasound is the appropriate first-line imaging study. Findings in hypothyroid-related liver disease may include:

• Increased hepatic echogenicity (suggesting steatosis)
• Normal or slightly enlarged liver
• Normal bile ducts
• Absence of focal lesions

If ultrasound is inconclusive or if there is concern for advanced fibrosis, FibroScan (transient elastography) can non-invasively assess liver stiffness.

Levothyroxine Therapy and Liver Enzyme Normalization

The primary treatment for hypothyroid-related liver enzyme elevation is thyroid hormone replacement with levothyroxine (LT4). Multiple studies have demonstrated that appropriate LT4 therapy leads to normalization of liver enzymes in the majority of patients.

A study published in Thyroid found that 80-90% of patients with hypothyroidism and elevated liver enzymes achieved normalization within 6 months of achieving a euthyroid state (normal TSH). However, patients with co-existing NAFLD may have persistent enzyme elevation even after thyroid function normalizes, requiring additional NAFLD-directed management.

Target TSH and Monitoring

The American Thyroid Association recommends targeting a TSH level within the laboratory reference range (typically 0.4-4.0 mIU/L) for most patients. In patients with persistent liver enzyme elevation despite TSH normalization, the target TSH may be adjusted to the lower half of the reference range (0.4-2.0 mIU/L) to optimize hepatic thyroid hormone activity, though this must be balanced against the risks of overtreatment.

Monitoring recommendations:

• Check TSH and free T4 6-8 weeks after starting or adjusting levothyroxine
• Repeat liver function tests at the same intervals until enzymes normalize
• Once stable, monitor TSH and liver enzymes every 6-12 months
• If liver enzymes have not normalized after 6 months of euthyroidism, evaluate for co-existing liver disease

Managing Co-Existing NAFLD

For patients whose liver enzyme elevation persists after thyroid normalization, NAFLD management should follow standard guidelines:

• Weight loss of 7-10% of body weight for overweight or obese patients
• Mediterranean diet or similar whole-food dietary approach
• Regular aerobic exercise (at least 150 minutes per week)
• Glycemic control in patients with diabetes or insulin resistance
• Lipid management with statins when indicated (monitor liver enzymes 12 weeks after starting)
• Avoidance of excessive alcohol consumption

Can subclinical hypothyroidism cause elevated liver enzymes?

Yes. Even subclinical hypothyroidism, characterized by elevated TSH with normal free T4 levels, can cause mild liver enzyme elevation. Studies have shown that 10-25% of patients with subclinical hypothyroidism have elevated ALT, and treatment with levothyroxine has been shown to improve liver enzymes in some but not all patients with subclinical disease. The decision to treat subclinical hypothyroidism for liver enzyme normalization should be individualized, considering the TSH level, presence of symptoms, other risk factors, and patient preference.

Will my liver enzymes normalize once my thyroid is treated?

In the majority of cases, yes. Approximately 80-90% of patients with hypothyroidism-related liver enzyme elevation achieve normalization within 3-6 months of achieving a euthyroid state with levothyroxine therapy. The enzymes that normalize fastest are typically those related to muscle (CK and AST from myopathy), while ALT related to steatosis may take longer. If your liver enzymes remain elevated after 6 months of normal TSH levels, your doctor should evaluate for other contributing causes, most commonly NAFLD, which may require additional treatment beyond thyroid hormone replacement.

Should I be tested for thyroid problems if my liver enzymes are elevated?

Yes, thyroid function testing (at minimum a TSH level) should be part of the standard evaluation for unexplained elevated liver enzymes. The American College of Gastroenterology and the American Association for the Study of Liver Diseases both recommend considering thyroid disease in the differential diagnosis of abnormal liver function tests. This is particularly important when the enzyme elevation is mild and persistent, when the patient has symptoms of thyroid dysfunction (fatigue, weight gain, cold intolerance, constipation, dry skin), or when the patient has a personal or family history of autoimmune disease.

Can thyroid medication itself cause elevated liver enzymes?

Levothyroxine, the standard treatment for hypothyroidism, is not hepatotoxic and does not cause elevated liver enzymes. In fact, initiating levothyroxine in hypothyroid patients typically lowers liver enzymes. However, there are some important considerations: excessively high doses of levothyroxine causing iatrogenic hyperthyroidism can paradoxically affect liver enzymes, though this is rare. Additionally, if you are switching between thyroid medication brands or formulations, transient changes in thyroid hormone levels may temporarily affect liver enzymes. Rarely, desiccated thyroid extract (Armour Thyroid, Nature-Throid) has been associated with liver enzyme changes in sensitive individuals, though this is not well-documented in the literature.

Is the liver damage from hypothyroidism permanent?

In the vast majority of cases, no. Hypothyroidism-related liver enzyme elevation results from functional impairment rather than permanent structural damage. Once thyroid hormone levels are restored to normal, the mechanisms causing enzyme elevation (reduced blood flow, membrane permeability changes, myopathy, and mild steatosis) are reversible. The liver has remarkable regenerative capacity, and most patients experience complete resolution of enzyme abnormalities. The exception is when hypothyroidism has contributed to advanced NAFLD with significant fibrosis, which may not fully reverse even with thyroid treatment. This is another reason why early detection and treatment are important.

Are there specific diets that help both thyroid and liver health?

While no single diet treats both conditions definitively, certain dietary approaches can support both thyroid and liver health simultaneously. The Mediterranean diet, rich in fruits, vegetables, whole grains, olive oil, fish, and nuts, has the strongest evidence base for NAFLD improvement and also provides adequate selenium and zinc, which are important for thyroid hormone metabolism. Adequate iodine intake (from iodized salt, seafood, and dairy) supports thyroid function, while limiting processed foods, added sugars, and excessive saturated fat benefits the liver. Patients with Hashimoto thyroiditis may benefit from adequate selenium (200 mcg/day), which has been shown to reduce thyroid antibody levels, though its direct effect on liver enzymes is less clear. Always discuss dietary changes and supplements with your healthcare provider.

The relationship between hypothyroidism and elevated ALT and AST is well-established and clinically significant. Through mechanisms including reduced hepatic blood flow, fatty liver development, cholestasis, and myopathy, thyroid hormone deficiency directly impacts liver enzyme levels in up to 55% of untreated patients.

The encouraging news is that this connection is also highly treatable. Appropriate levothyroxine therapy normalizes liver enzymes in the vast majority of patients within 3-6 months, and the liver changes associated with hypothyroidism are typically reversible. The key is recognition: patients with unexplained elevated liver enzymes should be screened for thyroid dysfunction, and patients with known hypothyroidism should have their liver enzymes monitored as part of their routine care.

For patients with persistent liver enzyme elevation despite normalized thyroid function, co-existing NAFLD is the most common explanation, and lifestyle modifications including weight loss, dietary changes, and exercise remain the cornerstone of management.

If you are managing both thyroid and liver health concerns, WellAlly provides comprehensive tracking tools that let you monitor your thyroid function tests and liver enzyme trends in one unified platform. Sign up today to take a more coordinated approach to your metabolic health.